

Resource Summary Report

Generated by [dkNET](#) on Aug 6, 2026

PE anti-human EGFR

RRID:AB_10896794

Type: Antibody

Proper Citation

BioLegend Cat# 352904, RRID:AB_10896794

Antibody Information

URL: http://antibodyregistry.org/AB_10896794

Proper Citation: BioLegend Cat# 352904, RRID:AB_10896794

Target Antigen: EGFR

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PE anti-human EGFR

Description: This monoclonal targets EGFR

Target Organism: human

Clone ID: Clone AY13

Antibody ID: AB_10896794

Vendor: BioLegend

Catalog Number: 352904

Alternative Catalog Numbers: 352903

Record Creation Time: 20250819T233224+0000

Record Last Update: 20250820T053857+0000

Ratings and Alerts

No rating or validation information has been found for PE anti-human EGFR.

No alerts have been found for PE anti-human EGFR.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#).

Hosking MP, et al. (2025) Preferential tumor targeting of HER2 by iPSC-derived CAR T cells engineered to overcome multiple barriers to solid tumor efficacy. *Cell stem cell*, 32(7), 1087.

Denk D, et al. (2025) IL-17RA signaling provides dual tumor-suppressor function during late-stage colorectal carcinogenesis. *Immunity*, 58(3), 701.

Barra JM, et al. (2024) Combinatorial genetic engineering strategy for immune protection of stem cell-derived beta cells by chimeric antigen receptor regulatory T cells. *Cell reports*, 43(11), 114994.

Shah Z, et al. (2024) Human anti-PSCA CAR macrophages possess potent antitumor activity against pancreatic cancer. *Cell stem cell*, 31(6), 803.

Tian M, et al. (2023) Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma. *Cell reports. Medicine*, 4(10), 101212.

Bosse KR, et al. (2022) Serial Profiling of Circulating Tumor DNA Identifies Dynamic Evolution of Clinically Actionable Genomic Alterations in High-Risk Neuroblastoma. *Cancer discovery*, 12(12), 2800.